menu
    • menu
    [{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Vectura Ltd","sponsor":"Incannex Healthcare","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"UNITED KINGDOM","productType":"Small molecule","year":"2021","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Vectura Ltd","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Vectura Ltd \/ Incannex","highestDevelopmentStatusID":"4","companyTruncated":"Vectura Ltd \/ Incannex"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Curia","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Cannabidiol","moa":"CB1 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"Incannex Healthcare \/ Curia Global","highestDevelopmentStatusID":"4","companyTruncated":"Incannex Healthcare \/ Curia Global"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"},{"orgOrder":0,"company":"Incannex Healthcare","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"AUSTRALIA","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Cannabidiol","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I","graph3":"Incannex Healthcare","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Incannex Healthcare \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Incannex Healthcare \/ Not Applicable"},{"orgOrder":0,"company":"Sedana Medical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SWEDEN","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Isoflurane","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Sedana Medical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Sedana Medical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Sedana Medical \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Isoflurane

    Menu

    Isoflurane

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vectura Ltd

                            United Kingdom
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Isoflurane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : Incannex Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Vectura Signs Pre-Clinical Development Agreement with Incannex to Advance IHL-216A for the Treatment of Trauma...

                            Details : Under the terms of the agreement, Vectura will undertake formulation screening studies, manufacturing process optimisation studies and stability assessments, as well as manufacturing a laboratory-scale batch of IHL-216A (Cannabidiol) to support toxicolog...

                            Brand Name : IHL-216A

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 22, 2021

                            Lead Product(s) : Cannabidiol,Isoflurane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : Incannex Healthcare

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Skyepharma Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

                            Details : Sedaconda (isoflurane) is an inhalation anesthetic that acts as a GABAA receptor modulator, decreasing motor function and inhibiting excitatory neurotransmission via NMDA receptors.

                            Brand Name : Sedaconda ACD

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 25, 2024

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sedana Medical Receives FDA Fast Track Designation in The United States

                            Details : Sedaconda (isoflurane), a general inhalation anesthetic, acts as a positive allosteric GABAA receptor modulator. It enhances glycine receptor activity, which decreases motor function and inhibits NMDA glutamate receptor, which mediates excitatory neurotr...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 04, 2023

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Incannex Healthcare

                            Australia arrow
                            Antibody Engineering
                            Not Confirmed

                            Incannex Healthcare

                            Australia arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Isoflurane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Incannex Completes Positive Pre-IND Meeting with US FDA on IHL-216A for Treatment of Concussion and Traumatic ...

                            Details : IHL-216A (cannabidiol) is a CB1 receptor negative allosteric modulator. It is being evaluated in preclinical studies in combination with Isoflurane for the treatment of traumatic brain injury & concussion.

                            Brand Name : IHL-216A

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 11, 2022

                            Lead Product(s) : Cannabidiol,Isoflurane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Incannex Healthcare

                            Australia arrow
                            Antibody Engineering
                            Not Confirmed

                            Incannex Healthcare

                            Australia arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Cannabidiol,Isoflurane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Preclinical

                            Sponsor : Curia

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Incannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A

                            Details : IHL-216A (cannabidiol) has been observed to have a greater neuroprotective effect in a rodent model of sports concussion than CBD, and results indicate restoration of the spatial memory deficit post-concussion with IHL-216A administration.

                            Brand Name : IHL-216A

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            August 02, 2022

                            Lead Product(s) : Cannabidiol,Isoflurane

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Preclinical

                            Sponsor : Curia

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sedana Medical receives IND approval for US trials

                            Details : Company received IND clearance from the USFDA to initiate phase III pivotal clinical trials with its combination registration of medical device Sedaconda ACD and pharmaceutical Sedaconda (isoflurane) for sedation of mechanically ventilated intensive care...

                            Brand Name : Sedaconda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            December 23, 2021

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sedana Medical Submits IND for US Clinical Trials

                            Details : Sedaconda (isoflurane) for inhaled sedation used in combination with medical device Sedaconda ACD, it's primary endpoint in each study will is effective and non-inferior to propofol for sedation of mechanically ventilated patients in the intensive care u...

                            Brand Name : Sedaconda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 24, 2021

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sedana Medical Receives Approval for European Dossier

                            Details : The topline results, announced in July 2020, showed that the study reached its primary goal; to show that Sedaconda administered via AnaConDa is an effective sedation method for ventilated ICU patients, comparable to propofol.

                            Brand Name : Sedaconda

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 20, 2021

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed

                            Sedana Medical

                            Sweden arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Sedana Medical Announces Positive Top Line Result in Pivotal IsoConDa Study

                            Details : The results indicate that IsoConDa is an effective and safe sedation method and will form the basis for the company's application for European market approval later this autumn.

                            Brand Name : IsoConDa

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 10, 2020

                            Lead Product(s) : Isoflurane

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth